Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of PF-06881894 (Nyvepria) vs Neulasta in Healthy Volunteers
NCT03273842Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2017
- Primary completion
- Jul 2018
- Modality
- PEGylated Peptides, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pegfilgrastim-apgf in neutropenia (2 arms), sponsored by Pfizer. Primary endpoint: Proportion of subjects with negative baseline and confirmed postdose positive anti-pegfilgrastim antibody test result at 90 days. Started Oct 2017; status: completed.
02
Drugs
pegfilgrastim-apgf
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT03273842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03273842.